208 related articles for article (PubMed ID: 11200206)
21. Metabolic bone disease induced by prostate cancer: rationale for the use of bisphosphonates.
Berruti A; Dogliotti L; Tucci M; Tarabuzzi R; Fontana D; Angeli A
J Urol; 2001 Dec; 166(6):2023-31. PubMed ID: 11696699
[TBL] [Abstract][Full Text] [Related]
22. The management of painful bone metastases with an emphasis on radionuclide therapy.
Hillegonds DJ; Franklin S; Shelton DK; Vijayakumar S; Vijayakumar V
J Natl Med Assoc; 2007 Jul; 99(7):785-94. PubMed ID: 17668645
[TBL] [Abstract][Full Text] [Related]
23. Bisphosphonates to prevent skeletal complications in men with metastatic prostate cancer.
Smith MR
J Urol; 2003 Dec; 170(6 Pt 2):S55-7; discussion S57-8. PubMed ID: 14610411
[TBL] [Abstract][Full Text] [Related]
24. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer.
Small EJ; Smith MR; Seaman JJ; Petrone S; Kowalski MO
J Clin Oncol; 2003 Dec; 21(23):4277-84. PubMed ID: 14581438
[TBL] [Abstract][Full Text] [Related]
25. [Efficiency of second-generation bisphosphonate in treating patients with prostate cancer and bone metastases].
Musaev TN; Kerimov AKh; Ali-zade AM
Georgian Med News; 2008 Nov; (164):14-8. PubMed ID: 19075335
[TBL] [Abstract][Full Text] [Related]
26. [Radionuclide therapy for the treatment of skeletal metastases of urological malignancies: a forgotten therapy?].
Badawi JK
Dtsch Med Wochenschr; 2012 Aug; 137(33):1645-9. PubMed ID: 22875692
[TBL] [Abstract][Full Text] [Related]
27. Integrating bone targeting radiopharmaceuticals into the management of patients with castrate-resistant prostate cancer with symptomatic bone metastases.
Blacksburg SR; Witten MR; Haas JA
Curr Treat Options Oncol; 2015 Mar; 16(3):325. PubMed ID: 25777571
[TBL] [Abstract][Full Text] [Related]
28. Treatment of bone complications in advanced prostate cancer: rationale for bisphosphonate use and results of a phase III trial with zoledronic acid.
Saad F
Semin Oncol; 2002 Dec; 29(6 Suppl 21):19-27. PubMed ID: 12584691
[TBL] [Abstract][Full Text] [Related]
29. Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton.
Pelger RC; Hamdy NA; Zwinderman AH; Lycklama à Nijeholt AA; Papapoulos SE
Bone; 1998 Apr; 22(4):403-8. PubMed ID: 9556142
[TBL] [Abstract][Full Text] [Related]
30. The role of bisphosphonates in the management of metastatic prostate cancer.
Michaelson MD; Smith MR
Curr Oncol Rep; 2003 May; 5(3):245-9. PubMed ID: 12667423
[TBL] [Abstract][Full Text] [Related]
31. The use of bisphosphonates in patients with breast cancer.
Van Poznak CH
Cancer Control; 2002; 9(6):480-9. PubMed ID: 12514566
[TBL] [Abstract][Full Text] [Related]
32. Utilization of palliative radiotherapy for breast cancer patients with bone metastases treated with bisphosphonates-Toronto Sunnybrook Regional Cancer Centre experience.
Enright K; Clemons M; Chow E
Support Care Cancer; 2004 Jan; 12(1):48-52. PubMed ID: 14577020
[TBL] [Abstract][Full Text] [Related]
33. The treatment of osseous metastases of hormone-refractory prostate cancer with external beam radiotherapy and Strontium-89.
De Ruysscher D; Spaas P; Specenier P
Acta Urol Belg; 1996 Sep; 64(3):13-9. PubMed ID: 8946776
[TBL] [Abstract][Full Text] [Related]
34. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
35. Palliative treatment of bone metastases in hormone-refractory prostate cancer: effects of pamidronate on the carboxyterminal telopeptide of type-I collagen level in patients with increasing prostate-specific antigen levels.
Kawashima H; Tanaka T; Kuratsukuri K; Uchida J; Sugimura K; Tamada S; Nishisaka N; Kumata K; Iwai Y; Ikemoto S; Ezaki K; Nakatani T
Urol Int; 2007; 78(4):345-50. PubMed ID: 17495494
[TBL] [Abstract][Full Text] [Related]
36. [Radiotherapy and bisphosphonate therapy in bone metastases of prostate carcinoma].
Seegenschmiedt MH; Oppenkowski R
Praxis (Bern 1994); 2001 Sep; 90(38):1645-52. PubMed ID: 11675918
[TBL] [Abstract][Full Text] [Related]
37. Preservation of bone health in prostate cancer.
Lattouf JB; Saad F
Curr Opin Support Palliat Care; 2007 Oct; 1(3):192-7. PubMed ID: 18685362
[TBL] [Abstract][Full Text] [Related]
38. New bisphosphonates in the treatment of bone metastases.
Averbuch SD
Cancer; 1993 Dec; 72(11 Suppl):3443-52. PubMed ID: 8242577
[TBL] [Abstract][Full Text] [Related]
39. TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.
James N; Pirrie S; Pope A; Barton D; Andronis L; Goranitis I; Collins S; McLaren D; O'Sullivan J; Parker C; Porfiri E; Staffurth J; Stanley A; Wylie J; Beesley S; Birtle A; Brown J; Chakraborti P; Russell M; Billingham L
Health Technol Assess; 2016 Jul; 20(53):1-288. PubMed ID: 27434595
[TBL] [Abstract][Full Text] [Related]
40. The role of bisphosphonates in the management of bone metastases in prostate cancer.
Saad F; Chi K; Fleshner N
Can J Urol; 2004 Oct; 11(5):2376-82. PubMed ID: 15576002
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
